Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05537922 · ClinicalTrials.gov registry record
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
A clinical trial of Non-Small Cell Lung Cancer and Lung Adenocarcinoma, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
- Recruiting
- Registry status
- 2,200
- Enrollment target
- 4
- Study locations
NCT05537922 is a study of Non-Small Cell Lung Cancer and Lung Adenocarcinoma that is actively recruiting participants, run by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. The registered enrollment target is 2,200 participants, above the 654-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (236% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT05537922, a study of Non-Small Cell Lung Cancer and Lung Adenocarcinoma, is actively recruiting participants, sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
- RECRUITING
- Registry status
- 2,200 participants
- Enrollment target
- 4
- Study locations
Study Summary
I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of available data from 2000 patients - and a prospective - multi-omics prospective data collection in 200 NSCLS patients - study phase. The retrospective cohort will be used to perform a preliminary knowledge extraction phase and to build a retrospective predictive model for IO (R-Model), that will be used in the prospective study phase to create a first version of the PDSS tool, an AI-based tool to provide an easy and ready-to-use access to predictive models, increasing care appropriateness, reducing the negative impacts of prolonged and toxic treatments on wellbeing and healthcare costs. The prospective part of the project includes the collection and the analysis of multi-OMICs data from a multicentric prospective cohort of about 200 patients. This cohort will be used to validate the results obtained from the retrospective model through the creation of a new model (P-Model), which will be used to create the final PDSS tool.
Conditions Studied
Study Locations (4)
Other
- Metropolitan Hospital - Athens
- Shaare Zedek Medical Center - Jerusalem
- Vall D'Hebron Institute of Oncology - Barcelona
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,200 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2027-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05537922
The ClinicalTrials.gov registry entry for NCT05537922 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 654-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (236% higher). The listed sponsor is Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT05537922 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Other, Illinois.
Frequently Asked Questions
What is clinical trial NCT05537922 about?
NCT05537922 is a clinical study titled "I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy". I3LUNG is an international project aiming to develop a medical device to predict immunotherapy efficacy for NSCLC patients using the integration of multisource data (real word and multi-omics data). This objective will be reached through a retrospective - setting up a transnational platform of avail...
What is the current status of trial NCT05537922?
This trial is currently recruiting. The enrollment target is 2,200 participants. The study started on 2022-10-01. Estimated completion is 2027-10-01.
What conditions does trial NCT05537922 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Cancer Metastatic, Lung Cancer, Nonsmall Cell.
Who is sponsoring clinical trial NCT05537922?
This trial is sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05537922 being conducted?
This trial has 4 study locations across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.